PDCD1 and cancer: Anti-programmed cell death 1 (PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) checkpoint inhibitors have known efficacy in MSI-H cancers, as well as TMB-high cancers [55,56].